Medibase
EN VI JA

Medicines

Tendering & Market Access

Public procurement of medicines under the 2023 Bidding Law and Circular 40/2025/TT-BYT, and reimbursement through Vietnam Social Security.

Overview

This section is a Vietnam-focused reference for public procurement and market access of medicines, governed by the Ministry of Health and Vietnam Social Security.

Scope:

  • Tender group classification — 5 groups for chemical and biological generics, 4 groups for herbal and traditional medicines — based on GMP standard (EU-GMP, PIC/S-GMP, WHO-GMP), origin, bioequivalence data, and reference-biologic status.
  • Centralized procurement at national level (National Centralized Drug Procurement Center — NCDPC, under MOH), provincial centralised procurement, and individual healthcare-facility tenders.
  • Inclusion in the health-insurance-reimbursable drug list (Circular 20/2022/TT-BYT) and payment ratios/conditions by hospital tier.
  • Hospital classification (Tier I/II/III/IV and special hospitals) and which tender groups each tier may procure from.
  • Original brand-name drugs and reference biologicals — conditions under which public facilities may procure them.
  • Price negotiation route for selected high-cost medicines.

The post-2023 framework — Bidding Law 22/2023/QH15, Decree 24/2024/ND-CP, and Circular 40/2025/TT-BYT — replaced the previous regime (Circulars 15/2019 → 07/2024 → 40/2025) to address chronic drug-supply disruptions caused by tender delays and to formalise mid-contract drug substitution.

Key documents

Procurement law:

  • Law on Bidding No. 22/2023/QH15 — issued 23 June 2023, effective 1 January 2024. Replaces the 2013 Bidding Law (43/2013/QH13). Article 55 carries provisions specific to drug, chemical, testing-reagent, and medical-equipment procurement.

Implementing decree:

  • Decree 24/2024/ND-CP — issued 27 February 2024. Detailed implementation of the Bidding Law on contractor selection, with a dedicated chapter on pharmaceutical procurement.

Drug tendering — current authority:

  • Circular 40/2025/TT-BYT — effective 25 October 2025. Replaces Circular 07/2024/TT-BYT in full. Drug bidding at public medical facilities; aligned with Pharmacy Law 44/2024/QH15. Five tender groups for chemical/biological generics, four for herbal and traditional medicines. Introduces mid-contract drug-substitution rules and updated provisions for traditional medicines and medicinal materials.

Drug tendering — historical (superseded):

  • Circular 07/2024/TT-BYT — issued 17 May 2024; in force only until Circular 40/2025 took effect.
  • Circular 06/2023/TT-BYT — amended Circular 15/2019; superseded with its parent.
  • Circular 15/2019/TT-BYT — issued 11 July 2019, effective 1 October 2019; replaced by Circular 07/2024.

Health insurance & reimbursement:

  • Health Insurance Law No. 25/2008/QH12 — original health-insurance framework.
  • Law No. 51/2024/QH15 — amends the Health Insurance Law; passed 27 November 2024, effective 1 July 2025. Notable changes: 100% co-payment relief for participants with 5+ years of continuous coverage, four new categories eligible for state-funded contributions, and formal coverage of home-based treatment.
  • Circular 20/2022/TT-BYT — issued 31 December 2022, effective 1 March 2023. List, payment ratios, and conditions for health-insurance reimbursement of chemical drugs, biologicals, radiopharmaceuticals, and tracers. Replaces Circulars 30/2018, 01/2020, and 20/2020.

Note: A draft amendment to Circular 20/2022 has been in public consultation; verify the currently effective version before relying on the appended list for commercial decisions.

Source documents

Direct links to the official text on government portals.

Primary law:

Decree:

  • Decree 24/2024/ND-CP — implementing the Bidding Law.

Drug-tender circular:

  • Circular 07/2024/TT-BYT — drug-tender groups, dossiers, evaluation rules at public healthcare facilities.
  • Circular 40/2025/TT-BYT — amendments to Circular 07/2024 (technical specifications, plan timing).

Operational portals:

Medibase cross-references:

  • Pricing — /medicine/pricing/
  • Registration process — /medicine/registration/

Recent updates

2025 — Circular 40/2025/TT-BYT in force: Effective 25 October 2025. Fully replaces Circular 07/2024 and aligns drug tendering with the amended Pharmacy Law (44/2024/QH15). Adds rules for drug substitution when winning bid drugs are withdrawn or otherwise unavailable, and clarifies bidding for traditional medicines and medicinal materials.

2025 — Amended Health Insurance Law in force: Law 51/2024/QH15 took effect on 1 July 2025. Market-access-relevant changes: 100% co-payment relief for long-term participants, four new categories of state-funded contributors, and formal coverage of home-based treatment under health insurance.

2024 — Drug-tendering reform package: Circular 07/2024/TT-BYT (17 May 2024) replaced Circular 15/2019 and its 06/2023 amendment. Issued together with Decree 24/2024/ND-CP (27 February 2024), it implemented the 2023 Bidding Law for the pharmaceutical sector and aimed to address persistent drug-supply disruptions caused by tender delays at hospitals.

2024 — Bidding Law in force: Law 22/2023/QH15 took effect on 1 January 2024, replacing the 2013 Bidding Law. Article 55 establishes a specific procurement regime for medicines and medical equipment and gives public facilities greater autonomy in purchasing non-BHYT items and immunisation vaccines.

2023 — Stop-gap tendering rules: Circular 06/2023/TT-BYT amended Circular 15/2019 to address acute drug shortages — mainly simplifications around tender package preparation, plan approval, and group changes — pending the full overhaul under Circular 07/2024.

Resources & links

Government & regulator:

  • Ministry of Health (MOH) — https://moh.gov.vn — announcements on bidding-law circulars and implementation guidance.
  • Drug Administration of Vietnam (DAV) — https://dav.gov.vn — drug registration, reference biologics list, original brand-name drug list.
  • Vietnam Social Security — https://baohiemxahoi.gov.vn — health-insurance participation, reimbursement, and fund management.
  • National Centralized Drug Procurement Center (under MOH) — list of medicines under national centralised procurement and tender results.
  • National e-Procurement System — https://muasamcong.mpi.gov.vn — public tender notices, plan documents, and contract awards.

Industry & analysis:

  • Vietnam Regulatory Affairs Society (VNRAS) — https://vnras.com — practitioner annotations on tendering circulars and amendments.
  • Pharma Group at EuroCham Vietnam — R&D-based industry policy dialogue on tendering and pricing.
  • Vietnam Pharmaceutical Companies Association (VNPCA).

Reference & official text:

Legal basis

See the full legal register →

Page changelog

2026-06-28: Trust-infrastructure retrofit. Document references cover the Bidding Law 22/2023/QH15 framework and the 2024–2025 drug-tender reform package (Circular 07/2024 + Circular 40/2025).

Effective from:
2024-01-01
Last reviewed:
2026-06-28
Page updated:
2026-10-27

Related topics — Medicines

Drug Registration Process in Vietnam

End-to-end analysis of marketing-authorisation workflow at the Drug Administration of Vietnam (DAV) — legal basis, dossier requirements, evaluation steps, statutory vs real-world timelines, and practical pitfalls under the amended Pharmacy Law (44/2024/QH15, in force 1 July 2025) and Circular 12/2025/TT-BYT.

Pricing

Drug-price declaration, winning tender prices, and the price-management framework under the 2023 Price Law and the 2024 Pharmacy Law amendment.

Pharmacovigilance

Adverse drug reaction reporting, vaccine-safety surveillance, and risk management under the Drug Administration of Vietnam and the National DI & ADR Centre.

Pharmaceutical Distribution & Retail in Vietnam

Licensing for wholesalers, community pharmacies, drug shops, commune health-station drug cabinets, and traditional-medicine retailers under the post-1 July 2025 framework — the Pharmacy Business Eligibility Certificate, Good Distribution Practice (GDP), Good Pharmacy Practice (GPP), and Good Storage Practice (GSP), as reshaped by amended Pharmacy Law 44/2024/QH15 and Decree 163/2025/ND-CP.

Drug Import & Export in Vietnam

Two regimes — ordinary commercial trade in drugs with valid marketing authorisation, and the special import-export of drugs without registration number — under Pharmacy Law Article 60 and new Article 53a (added by Law 44/2024/QH15), Decree 163/2025/ND-CP Chapter IV, the Customs Law 54/2014/QH13, and the 1961 Hague Apostille Convention from 11 September 2026.

Clinical Trials & Bioequivalence in Vietnam

Authorisation, GCP, ethics review and BE-study requirements under Pharmacy Law Chapter XI as implemented by Decree 163/2025/ND-CP Article 23, the new Circular 50/2025/TT-BYT (effective 27 February 2026; replaces Circular 29/2018/TT-BYT, Article 9 of Circular 10/2020/TT-BYT, and Circular 08/2014/TT-BYT), Circular 43/2024/TT-BYT on ethics committees, and Circular 07/2022/TT-BYT on the BE-required substance list.

Related news — Medicine

Back to Medicines

Reference information only; not legal or medical advice.